TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23427865
Drug: Infusion rate
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rate of 0.5 mL/min
Study: 11551130
Drug: Cisplatin-containing regimens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin-containing regimens concurrent with radiation therapy
Study: 8011000
Drug: Fluorocarbon-free GTN
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorocarbon-free GTN pump spray with high ethanol content (TH)
Study: 376236
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Heparin therapy
Study: 31816306
Drug: Outpatient ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Outpatient ibuprofen plus hydrocodone‐acetaminophen (opioid, n=85)
Study: 23670707
Drug: Canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 100 mg/day
Study: 25217230
Drug: Whole-brain radiotherapy
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-brain radiotherapy in primary therapy of PCNSL
Study: 21343556
Drug: Denosumab 120
Normalized name: DENOSUMAB 120 MG/1.7 ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 120 mg (subcutaneous, monthly)
Study: 21343556
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg (intravenous, dose adjusted for renal impairment)
Study: 9176034
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (200 mg zinc sulphate, 500 mg ascorbic acid, 600 mg alpha-tocopherol, 30 mg beta-carotene daily for 8 weeks)
Study: 2858421
Drug: Reproterol (0.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproterol (0.28 mg/kg)
Study: 2858421
Drug: Salbutamol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (0.1 mg/kg)
Study: 26787796
Drug: i-gel SGA
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel SGA
Study: 22670598
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg every 6 h)
Study: 20492655
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg plus simvastatin 20 mg (EZ + simva 10/20 mg)
Study: 19167588
Drug: ezetimibe +
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ezetimibe + pravastatin 10 to 40 mg/d
Study: 15278749
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 mg/day) for 12 months
Study: 7863047
Drug: Continuous Ambulatory
Normalized name: Continuous ambulatory peritoneal dialysis solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Ambulatory Oxygen Therapy (CAOT) - Group B
Study: 172561
Drug: Formalin‐inactivated decavalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formalin‐inactivated decavalent rhinovirus vaccine 1
Study: 29672740
Drug: Vadadustat 450
Normalized name: vadadustat 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vadadustat 450 mg once daily (QD)
Study: 29672740
Drug: Vadadustat 450
Normalized name: vadadustat 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vadadustat 450 mg thrice weekly (TIW)
Study: 29672740
Drug: Overall (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall (all dose cohorts)
Study: 29633515
Drug: Intermittent docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent docetaxel (35 mg/m2 weekly or 75 mg/m2 every 3 weeks)
Study: 25073921
Drug: Buffered saline
Normalized name: Phosphate Buffered Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered saline solution
Study: 17511155
Drug: Compositae salviae
Normalized name: Salvia sclarea seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compositae salviae dropping pill (CSDP)
Study: 11874410
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral hydrocortisone replacement (15 mg at 0800, 5 mg at 1700)
Study: 7562888
Drug: Nifedipine-GITS 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine-GITS 30 mg
Study: 2161295
Drug: Carboplatin 300
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 300 or 400 mg/m2 every 4 weeks
Study: 7315769
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no fluoride supplements)
Study: 7315769
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg fluoride as sodium fluoride
Study: 7315769
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg fluoride as sodium fluoride
Study: 26481215
Drug: Docetaxel 60
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m² and bevacizumab 15 mg/kg (Level 0 cohort)
Study: 26481215
Drug: Docetaxel 50
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 50 mg/m² and bevacizumab 15 mg/kg (Level 1 cohort)
Study: 22873656
Drug: Amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin plus metronidazole (375 mg amoxicillin and 500 mg metronidazole, three times daily for 7 days)
Study: 8473551
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of clentiazem (20 mg)
Study: 8473551
Drug: Oral (PO)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (PO) administration of clentiazem (80 mg)
Study: 2869591
Drug: Somatostatin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (250 micrograms bolus followed by 300 micrograms/hr infusion)
Study: 28595285
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without bevacizumab (Control)
Study: 29694465
Drug: Melatonin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (12 mg/day)
Study: 25516139
Drug: 200,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200,000 IU vitamin D3 monthly for two months then 100,000 IU monthly for a total of 18 months
Study: 18728266
Drug: Allopurinol, 200
Normalized name: Allopurinol, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol, 200 mg twice daily for 4 weeks
Study: 14651755
Drug: Evidence Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence Based Medicine (EBM) Knowledge Score; average score on the 12-point scale was 6.4; over 50% of respondents answered questions satisfactorily regarding critical appraisal methods and interpretation of results.
Study: 28386694
Drug: Alcohol (1.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1.09 g ethanol kg-1 fat-free body mass)
Study: 15023830
Drug: Acupuncture (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (up to 12 treatments over three months)
Study: 11779264
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg/d or 120 mg/d)
Study: 9555668
Drug: Intravenous iron-saccharate
Normalized name: Iron saccharate
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron-saccharate and rhEPO treatment in group II patients
Study: 9555668
Drug: Intravenous iron-saccharate
Normalized name: Iron saccharate
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron-saccharate and rhEPO treatment in group IV patients
Study: 8288664
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 grams followed by 750 mg at 8 and 16 hours later for a total of one day)
Study: 8288664
Drug: Cefazolin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1 gram every 8 hours for 9 doses for a total of three days)
Study: 31317534
Drug: Standardized antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized antibiotic stewardship quality improvement program
Study: 31378975
Drug: Supportive periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive periodontal therapy (SPT) consisting of oral prophylaxis with oral hygiene instructions
Study: 31378975
Drug: Supportive periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive periodontal therapy (SPT) combined with subgingival instrumentation
Study: 31378975
Drug: Supportive periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive periodontal therapy (SPT)
Study: 27862178
Drug: rHSA/IFNα2a 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHSA/IFNα2a 600 μg
Study: 11218544
Drug: male and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: male and female condom plus N-9 products (vaginal suppositories, film, gel)
Study: 29271855
Drug: Lidocaine Spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine Spray (LS)
Study: 19290703
Drug: Standard methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard methadone treatment
Study: 11036470
Drug: Dose-intense M-VAC
Normalized name: M-2698
DrugBank: M-2698 (DB15431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-intense M-VAC with G-CSF support
Study: 11036470
Drug: Conventional-dose M-VAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose M-VAC
Study: 8977854
Drug: Antral washouts
Normalized name: ALCOHOL 64.7 g in 100 g TOPICAL GEL [Astral Organica Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antral washouts followed by antibiotics and topical nasal steroids
Study: 6242801
Drug: Highly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified porcine insulin zinc suspension (mixed)
Study: 18329126
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg daily plus placebo (monotherapy)
Study: 15949731
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with full-dose ATG regimen (Merieux) for 8 days
Study: 2668140
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ruscus extract and HMC
Study: 12611746
Drug: Donepezil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (10 mg/day)
Study: 15098800
Drug: Oxymorphone extended
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone extended release (ER) 5 mg
Study: 15098800
Drug: Oxymorphone extended
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone extended release (ER) 10 mg
Study: 15098800
Drug: Oxymorphone extended
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone extended release (ER) 10 mg every 12 hrs
Study: 15098800
Drug: Oxymorphone extended
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone extended release (ER) 20 mg every 12 hrs
Study: 15098800
Drug: Oxymorphone extended
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone extended release (ER) 40 mg every 12 hrs
Study: 8179173
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia (GA) with 0.1‐0.15 mg/kg midazolam and 10 micrograms/kg fentanyl prior to skin incision; maintenance included 65% nitric oxide in oxygen and 0.1 mg increments of fentanyl as required.
Study: 8179173
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg i.v.) administered 15 min before induction of anaesthesia.
Study: 8179173
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (no ibuprofen).
Study: 3035164
Drug: Sodium bicarbonate,
Normalized name: Sodium Bicarbonate, 325 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium bicarbonate, hydrogen peroxide, and sodium chloride (S/P) oral hygiene
Study: 3035164
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral hygiene procedures plus phase‐contrast demonstration
Study: 3035164
Drug: S/P oral
Normalized name: paregor/salol/Psn Ac/bism ss/p ORAL SUSPENSION, ORAL (FINAL DOSE FORM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S/P oral hygiene plus phase‐contrast demonstration
Study: 30064986
Drug: Heparin bridging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin bridging
Study: 19793142
Drug: Uninterrupted warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uninterrupted warfarin
Study: 3358822
Drug: Parenteral thiamin
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral thiamin supplementation (250 mg daily for 5 days)
Study: 3358822
Drug: Parenteral thiamin
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral thiamin supplementation (250 mg within 24 hr)
Study: 29490101
Drug: Omega‐3‐6‐9 Junior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega‐3‐6‐9 Junior (Nordic Naturals, Inc.) treatment (338 mg eicosapentaenoic acid, 225 mg DHA, and 83 mg GLA)
Study: 29490101
Drug: Canola oil
Normalized name: Canola Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canola oil (124 mg palmitic acid, 39 mg stearic acid, 513 mg linoleic acid, 225 mg α‐linolenic acid, and 1346 mg oleic acid)
Study: 24815101
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives (COCs)
Study: 9428849
Drug: Remifentanil 3-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 3-4 micrograms/kg and propofol 2 mg/kg
Study: 8291918
Drug: CPT-11 (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 (irinotecan hydrochloride) regimen B (40 mg/m2 for 5 days every 3-4 weeks)
Study: 8291918
Drug: CPT-11 (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 (irinotecan hydrochloride) regimen C (40 mg/m2 for 3 days every week)
Study: 8291918
Drug: CPT-11 (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 (irinotecan hydrochloride) regimen D (20 mg/m2 twice a day for 7 days every 3-4 weeks)
Study: 8291918
Drug: CPT-11 (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 (irinotecan hydrochloride) regimen A (200 mg/m2 once a day every 3-4 weeks)
Study: 17065352
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg uric acid i.v. in vehicle
Study: 17065352
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg vitamin C as a control antioxidant
Study: 9286047
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccines containing genetically detoxified PT
Study: 1390504
Drug: Aspirin 1200
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 1200 mg/day
Study: 4009497
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (urine pH 5.6)
Study: 31497876
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment
Study: 11864514
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 550 +/- 150 mg/d
Study: 11864514
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 900 +/- 150 mg/d
Study: 11864514
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 1500 +/- 150 mg/d
Study: 27264413
Drug: Low-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity statin therapy
Study: 27885786
Drug: Medium chain
Normalized name: Medium chain triglyceride
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium chain triglycerides (MCT) oil (6 g/d for 8 weeks)
Study: 25869389
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 5 mg once daily for 4 weeks, then every other day for an additional 4 weeks
Study: 25869389
Drug: Prednisone (PD)
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (PD) 40 mg once daily for the initial 2 weeks, tapered by 10 mg every 2 weeks during the 8-week study period
Study: 14758179
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus intravascular catheter-based heat exchange system (Alsius, Irvine, CA)
Study: 14758179
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (acetaminophen and cooling blankets)
Study: 11419818
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg once daily for 20 wk
Study: 11419818
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg b.i.d. for 20 wk
Study: 11419818
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg b.i.d. for 8 wk followed by lansoprazole 30 mg once daily for 12 wk ('step-up')
Study: 11419818
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg once daily for 8 wk followed by ranitidine 150 mg b.i.d. for 12 wk ('step-down')
Study: 8474318
Drug: 46 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 46 g parboiled white rice
Study: 8474318
Drug: 69 g
Normalized name: DIMETHICONE 3.69 g in 55 g CUTANEOUS CREAM [GOLDKIWI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 69 g parboiled white rice
Study: 20107198
Drug: High Fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Fat diet (low-carbohydrate diet < or =20 g/d)
Study: 18046669
Drug: 4.0 g
Normalized name: Menthol 4.0 g in 100 mL TOPICAL GEL [BIOCOOL ROLL TYPE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 g daily sevelamer dose
Study: 18046669
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g daily sevelamer dose
Study: 2208013
Drug: Immediate combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate combination chemotherapy
Study: 352507
Drug: CP (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP (cyclophosphamide 1 g/m2 on day 1 and prednisone 100 mg/m2 daily for five days)
Study: 352507
Drug: BCVP (CVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCVP (CVP plus BCNU 60 mg/m2 on day 1)
Study: 19117121
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g etofenamate (group 1)
Study: 16076380
Drug: Sevelamer hydrochloride
Normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer hydrochloride 2250 mg/day
Study: 16076380
Drug: Sevelamer hydrochloride
Normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer hydrochloride 3000 mg/day
Study: 10072008
Drug: Spinal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal sufentanil 7.5 microg + bupivacaine 2.5 mg + clonidine 50 microg
Study: 10072008
Drug: Spinal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal sufentanil 7.5 microg + bupivacaine 2.5 mg
Study: 7575051
Drug: Placebo (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5 mg nicotine polacrilex)
Study: 23729801
Drug: Ofatumumab 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab 0.3 mg
Study: 23729801
Drug: Ofatumumab 60
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab 60 mg
Study: 23729801
Drug: Ofatumumab 100
Normalized name: ofatumumab 100 MG in 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab 100 mg
Study: 19398651
Drug: PF‐00489791 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐00489791 10 mg
Study: 19398651
Drug: PF‐00489791 20/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐00489791 20/40 mg
Study: 15885525
Drug: Integrated dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated dual disorders treatments
Study: 10088066
Drug: Metoprolol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (up to 200 mg/day)
Study: 1836986
Drug: Cilazapril 2.5
Normalized name: cilazapril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 2.5 mg/day
Study: 2138051
Drug: Cilazapril (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (1.25 mg/day and 5.0 mg/day)
Study: 6772293
Drug: Adriamycin added
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin added to VAC chemotherapy
Study: 17328806
Drug: Amodiaquine plus
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine plus placebo (10 mg/kg/day x 3 d)
Study: 15465986
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active treatment (placebo)
Study: 11145479
Drug: Antithrombin treatment
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin treatment (100 U/kg BW during 24 hours)
Study: 9876448
Drug: Endolymphatic irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endolymphatic irradiation with lipoiodine containing 131I (specific activity 4-6 mCu/ml)
Study: 7989902
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion (10 ng kg‐1 min‐1) for 1 hour in EH
Study: 7989902
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion during sodium nitroprusside (NP) infusion in EH
Study: 9933789
Drug: Ultrasound contrast
Normalized name: ULTRASOUND CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound contrast agents